We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Our conditionally active biologics, or CABs, capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult […]

We initially intend to focus our search on target businesses in the education, training, reskilling, human capital and education technology industries.

Our focus will be on target companies with enterprise values of about $1 billion to $4 billion. We intend to capitalize on our management team’s ability to identify, acquire and operate businesses across a broad range of sectors, that may provide opportunities for attractive long-term risk-adjusted returns. Our sponsor is affiliated with Riverside Management Group (RMG), […]

We intend to focus our search for a target business in the biotechnology and/or telemedicine sector of the healthcare industry in North America.

We intend to focus our search on companies in the technology industry that are growing at an accelerated pace due to industry changes resulting from the COVID-19 pandemic. Lloyd Carney, our Chief Acquisition Officer, has spent over 30 years in the technology industry. Mr. Carney was the CEO of Brocade Communication Systems, which Broadcom acquired for […]

(This is the third SPAC, or special-purpose acquisition company, also known as a blank-check company, backed by True Wind Capital, a San Francisco-based private equity firm managing $1.1 billion as of June 2020. True Wind Capital is focused on investing in leading technology companies with a broad mandate including software, financial technology, industrial technology, healthcare IT, Internet, semiconductors […]

We intend to capitalize on the ability of our management team to identify promising opportunities in the biotechnology sector. Our sponsor, Frazier Lifesciences Sponsor LLC, is an affiliate of Frazier Healthcare Partners (“Frazier”), founded in 1991 as one of the first healthcare dedicated investment firms, with nearly $4.8 billion raised across 12 institutional funds. From 2005 […]

Our CEO and co-founder is John Delaney, a former Democratic presidential candidate, and a former Democratic congressman from Maryland. He is also the founder and the former CEO of two NYSE-listed companies. Steve Case, a co-founder of AOL and the CEO of Revolution LLC, is a co-founder of this blank-check company, or special-acquisition purpose company […]

(Note: The financial figures are in U.S. dollars for the six months ended June 30, 2020, according to the prospectus.) (Note: This is not an IPO. The listing here is only a professional courtesy. This French biotech company’s shares trade on the Euronext Paris under the symbol “NANO.” The stock lasted traded on the Euronext […]

Our business strategy is to identify, combine with and maximize the value of a company that has either recently emerged from bankruptcy court protection or will require incremental capital as part of a balance sheet restructuring. Our focus will be on companies with an enterprise value of approximately $750 million to $2 billion. The economic […]